Marco Colonna Selected Research

CD226 antigen

1/2015	Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models.
6/2013	Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marco Colonna Research Topics

Disease

37	Neoplasms (Cancer) 01/2022 - 10/2004
36	Infections 01/2021 - 12/2002
25	Inflammation (Inflammations) 01/2022 - 06/2003
21	Virus Diseases (Viral Diseases) 12/2021 - 02/2002
14	Alzheimer Disease (Alzheimer's Disease) 10/2021 - 03/2015
10	Melanoma (Melanoma, Malignant) 10/2014 - 06/2003
6	Bacterial Infections (Bacterial Infection) 01/2021 - 02/2009
4	Neuroinflammatory Diseases 01/2021 - 01/2016
4	Autoimmune Diseases (Autoimmune Disease) 05/2016 - 07/2007
4	Sepsis (Septicemia) 01/2016 - 06/2003
3	Neoplasm Metastasis (Metastasis) 04/2016 - 01/2010
2	Body Weight (Weight, Body) 01/2021 - 03/2007
2	Asthma (Bronchial Asthma) 01/2020 - 07/2007
2	Dysbiosis 01/2020 - 01/2019
2	Wounds and Injuries (Trauma) 01/2019 - 01/2009
2	Parasitic Diseases (Parasitic Disease) 01/2019 - 04/2014
2	Amyloid Plaque 01/2019 - 01/2018
2	Acute-Phase Reaction 01/2019 - 08/2005
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 12/2016
2	Malaria 12/2017 - 06/2013
2	Reinfection 10/2016 - 11/2014
2	Colitis 10/2015 - 01/2008
2	Multiple Myeloma 07/2015 - 05/2015
2	Demyelinating Diseases (Demyelinating Disease) 05/2015 - 02/2012
2	Atherosclerosis 04/2015 - 04/2012
2	Persistent Infection 01/2015 - 03/2004
2	Pneumococcal Pneumonia 08/2014 - 06/2014
2	Carcinogenesis 05/2014 - 03/2009
2	Confusion (Bewilderment) 04/2011 - 01/2011
2	Endotoxemia 08/2005 - 12/2004
1	COVID-19 01/2022
1	Weight Gain 01/2022
1	Nervous System Diseases (Neurological Disorders) 01/2022
1	Sialadenitis 04/2021
1	Brain Injuries (Brain Injury) 01/2021

Drug/Important Bio-Agent (IBA)

25	CytokinesIBA 02/2021 - 04/2003
20	LigandsIBA 11/2021 - 06/2003
11	Proteins (Proteins, Gene)FDA Link 12/2019 - 06/2003
10	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2016
8	AntigensIBA 02/2021 - 04/2003
8	Antiviral Agents (Antivirals)IBA 01/2021 - 01/2009
8	Interleukin-22 (IL-22)IBA 01/2021 - 02/2009
7	Interferon Type IIBA 01/2021 - 02/2002
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 05/2004
6	ChemokinesIBA 01/2019 - 06/2003
6	Toll-Like Receptors (Toll-Like Receptor)IBA 03/2016 - 06/2003
5	InterferonsIBA 01/2020 - 05/2010
5	Cell Surface ReceptorsIBA 01/2019 - 08/2005
5	LipidsIBA 01/2019 - 03/2015
5	NK Cell Lectin-Like Receptor Subfamily KIBA 05/2011 - 08/2005
4	Interleukin-6 (Interleukin 6)IBA 01/2022 - 03/2006
4	Interleukin-17 (Interleukin 17)IBA 10/2019 - 08/2013
4	class-I restricted T cell-associated moleculeIBA 01/2019 - 08/2005
4	Interferon-gamma (Interferon, gamma)IBA 01/2018 - 08/2005
4	Poly I-CIBA 10/2014 - 11/2008
4	Triggering Receptor Expressed on Myeloid Cells-1IBA 08/2014 - 12/2004
3	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 08/2013
3	Transcription Factors (Transcription Factor)IBA 12/2021 - 01/2016
3	Immunoglobulins (Immunoglobulin)IBA 11/2021 - 09/2003
3	AntibodiesIBA 11/2021 - 06/2004
3	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2019
3	Peptides (Polypeptides)IBA 01/2021 - 01/2015
3	VaccinesIBA 10/2020 - 05/2011
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 10/2016
3	Interleukin-13IBA 01/2020 - 01/2009
3	Natural Killer Cell ReceptorsIBA 01/2019 - 10/2006
3	AutoantigensIBA 01/2018 - 04/2011
3	Monoclonal AntibodiesIBA 04/2016 - 12/2002
3	DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA 04/2015 - 12/2002
3	Viral RNAIBA 04/2011 - 02/2010
2	NucleotidesIBA 04/2021 - 10/2014
2	Small Cytoplasmic RNAIBA 01/2021 - 01/2020
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 12/2019 - 01/2019
2	InterleukinsIBA 12/2019 - 01/2017
2	Interleukin-4 (Interleukin 4)IBA 01/2019 - 01/2009
2	Chemokine ReceptorsIBA 01/2019 - 01/2018
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2015 - 01/2008
2	CD226 antigenIBA 01/2015 - 06/2013
2	LipopolysaccharidesIBA 05/2014 - 08/2005
2	chenodeoxycholate sulfate conjugate (CDCS)IBA 09/2013 - 01/2011
2	flt3 ligand protein (flt3 ligand)IBA 06/2013 - 12/2008
2	RNA Helicases (RNA Helicase)IBA 05/2013 - 11/2008
2	PerforinIBA 01/2010 - 10/2004
2	Toll-Like Receptor 3IBA 12/2009 - 05/2006
2	NectinsIBA 03/2009 - 10/2006
2	Phenobarbital (Luminal)FDA Link 01/2009 - 01/2005
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 11/2008 - 05/2006
2	Interleukin-10 (Interleukin 10)IBA 12/2007 - 07/2007
2	Mitogen-Activated Protein KinasesIBA 09/2006 - 03/2006
1	Immune Checkpoint InhibitorsIBA 01/2022
1	GTP-Binding Proteins (G-Protein)IBA 04/2021
1	Purinergic P2Y2 ReceptorsIBA 04/2021
1	GhrelinIBA 01/2021
1	isothiocyanic acidIBA 01/2021
1	Hormones (Hormone)IBA 01/2021
1	HaptensIBA 01/2021
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2021

Therapy/Procedure

18	Therapeutics 01/2022 - 03/2004
8	Immunotherapy 02/2021 - 01/2015
1	Drug Therapy (Chemotherapy) 11/2021